Background {#Sec1}
==========

Leading clinical guidelines advise to screen and treat common mental disorders and symptoms among all pregnant women \[[@CR1], [@CR2]\]. Common mental disorders and symptoms generally refer to mood and anxiety disorders, including depression, phobias (including extreme fear of childbirth 'tokophobia'), generalized anxiety disorder, post-traumatic stress disorder, and obsessive-compulsive disorders \[[@CR2]\]. Prevalence rates of mental disorders during pregnancy are estimated as high as 12.4% for mood disorders and 15.2% for anxiety disorders \[[@CR3], [@CR4]\]. Next to the burden of these common mental disorders for the pregnant women, these disorders may be harmful for the offspring \[[@CR5]\]. Adverse effects on the offspring include almost 20% increased odds of low birth weight as compared to offspring from mothers without mental problems \[[@CR6]\]. Low birth weight in turn has repeatedly been linked to negative (long term) somatic outcomes such as all-cause mortality, stunted growth, respiratory problems, and obesity \[[@CR7]\]. In addition, low birth weight is associated with an increased risk for the development of mental problems \[[@CR8]\]. Other adverse effects of prenatal mental disorders on the (unborn) child include a 13% increased risk of premature birth \[[@CR6]\] and lower Apgar scores \[[@CR5]\]. Similar to the effects of low birth weight, children from women who had a mental disorder during pregnancy have a two to three times increased risk for the development of psychopathology \[[@CR9]\]. This includes an increased risk of symptoms of depression in (late) adolescence \[[@CR10]\], an increased risk of anxiety in the ages 6 to 9 years old, and internalizing and externalizing (psychiatric) problems at the ages 2 to 6 \[[@CR2], [@CR11], [@CR12]\]. Other risks for the offspring of pregnant women with common mental disorders include behavioral, motor, developmental, and cognitive problems such as attention-deficit hyperactivity disorder and an atypical (functional and structural) brain development \[[@CR2], [@CR9], [@CR13], [@CR14]\]. Theoretical accounts of the associations between prenatal mental health and offspring outcomes focus on a cascade of processes, such as activation of the stress-response (hypothalamic-pituitary-adrenal \[HPA\] axis), (epi)genetics, e.g., methylation of "stress" genes, elevated levels of intrauterine cytokines or glucocorticoids, and poor self-care during pregnancy (e.g., smoking, disturbed appetite) or poor mother-child attachment in the postpartum period due to the disabling nature of mental health problems \[[@CR10], [@CR14]--[@CR18]\].

Effective treatments for prenatal common mental disorders are therefore of paramount importance given the recurrent and life-long course of most mental disorders and their association with (chronic) somatic conditions \[[@CR19]\]. Although the exact mechanisms through which prenatal mental disorders exert an effect on offspring are currently unknown, the adverse outcomes themselves are clear. Current evidence-based treatments for mental disorders during pregnancy, i.e., medication and/or psychological interventions, are (implicitly) presumed to not only address mental needs of pregnant women, but also to confer prophylactic mental and physical benefits for offspring \[[@CR20], [@CR21]\]. As implied in the NICE guidelines, "The impact of any mental health problem may often require more urgent intervention than would usually be the case because of its potential effect on the foetus/baby (..)" \[[@CR2]\]. The most used treatment for these disorders during pregnancy is antidepressant medication (AD; 3.7% of all pregnant women in the UK up to 6.2% in the USA \[[@CR22], [@CR23]\]), followed by psychological therapies including cognitive behavioral therapy (CBT) \[[@CR24]\]. Supporting evidence for the benefits of these treatments is however limited, and the impact is typically restricted to the pregnant woman \[[@CR1], [@CR2], [@CR24], [@CR25]\]. Previous meta-analyses indicate that the evidence is restricted to psychological interventions for prenatal depression, for which CBT and interpersonal psychotherapy were shown to be most effective \[[@CR24]\].

Given that the recommended treatments for prenatal common mental disorders might paradoxically have an adverse effect on the offspring intrauterine, it is crucial to examine the effects of prenatal maternal treatments on offspring. To our knowledge, no meta-analyses of randomized controlled trials (RCTs) have examined the effect of various treatments on common mental disorders during pregnancy on offspring \[[@CR1], [@CR2], [@CR24], [@CR25]\]. One meta-analysis indicated a positive, but small effect of prenatal preventive and acute treatments for depression on child functioning only \[[@CR26]\]. Nonetheless, no conclusions regarding the effect of acute treatment for prenatal common mental disorders on offspring could be made, given that the majority of the studies that were included in this review included healthy pregnant women without (a history of) MDD or depressive symptoms (not acute treatment). Moreover, in the review, the authors did not assess the effects of acute treatment alone on child functioning. The last is the main aim of this meta-analysis, i.e., to examine the effect of prenatal treatments for common mental disorders on offspring outcomes. Some studies furthermore report adverse effects of prenatal antidepressants use on preterm birth, birth weight, and Apgar scores \[[@CR27]\], persistent pulmonary hypertension (PPHN) \[[@CR28], [@CR29]\], development \[[@CR30], [@CR31]\], and cardiovascular malformations \[[@CR32]\] in offspring. However, these reports are derived from non-randomized studies that do not permit conclusions of causality. The beneficial or possibly iatrogenic effects of psychological interventions on offspring are however less clear, despite the beneficial effects of psychotherapies for perinatal major depressive disorders as reported in previous meta-analyses \[[@CR24], [@CR25]\]. A review of the evidence from RCTs is timely and warranted. The primary aim of the current study was to conduct a meta-analysis to examine whether treatments for pregnant women with common mental disorders, as recommended in leading clinical guidelines (including antidepressants and psychotherapy) \[[@CR1], [@CR2]\], prevent adverse effects in offspring, both in terms of somatic and mental outcomes.

Method {#Sec2}
======

Search strategy and selection criteria {#Sec3}
--------------------------------------

This meta-analysis was conducted in accordance with the PRISMA guidelines and registered on PROSPERO \[[@CR33]\]. A search in PubMed, PsycInfo, Embase, and the Cochrane database of randomized trials was performed on articles published from their origin through April 2016 and updated up to August 31, 2017. Five search strings were composed using standardized vocabulary (e.g., MeSH terms and text words), terms for searching title and abstract, and Boolean operators. The full search string is presented in Additional file [1](#MOESM1){ref-type="media"}. The five key strings targeted pregnancy, common mental disorders, interventions, offspring outcomes, and study design.

Included studies needed to (1) be a (cluster) randomized controlled trial; (2) treat (3) one or more prenatal common mental disorders or high levels of symptoms; (4) compare an intervention to a control condition; (5) include at least one offspring outcome; and (6) report sufficient information to calculate effect sizes (or provide this information available upon request). Included common mental disorders and symptoms were mood disorders and anxiety disorders according to the definition of DSM-IV axis I and older \[[@CR34]\]. These included obsessive-compulsive disorders and trauma- and stress-related disorders/symptoms. Severe mental illnesses like bipolar disorder, psychosis, schizophrenia, or substance abuse were excluded due to the low prevalence rates \[[@CR2]\]. The common mental disorder or symptoms could be assessed by self-report measures or clinical interviews, provided that the participants were primarily selected based upon the presence of mental disorders or high symptom levels. The control condition was defined as care or treatment as usual, wait-list control, or placebo medication. Language was restricted to English and Dutch due to the language proficiency of the authors. Two authors (MEB and SG) independently screened and selected the articles and assessed the risk of bias using the seven criteria as proposed by the Cochrane Handbook for Systematic Reviews of Interventions. Disagreement was solved by consultation of a third rater (CLB) and reaching consensus. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework \[[@CR35]\] was used to assess the overall level of certainty and strength of evidence for each of the main offspring outcomes. The evidence for each of the main offspring outcomes was potentially downgraded based upon risk of bias, inconsistency, indirectness, imprecision, number of participants, and pooled effect sizes.

Offspring outcome measures {#Sec4}
--------------------------

The primary outcomes included all offspring variables collected in the neonatal period, during infancy and early childhood. They included Apgar scores, birth weight, gestational age, and measures of cognitive, motor, and emotional development. Examples of these variables are offspring depressive and anxiety symptoms (e.g., as assessed by the strengths and difficulties questionnaire \[[@CR36]\]), general development (e.g., Bayley scales of infant development \[[@CR37]\]), child behavior (e.g., child behavior checklist \[[@CR38]\]), neurodevelopmental problems (e.g., Brazelton neonatal behaviour assessment scale \[[@CR39]\]), and biological measures (e.g., cortisol levels, height, weight). No restrictions were made on the assessment instruments (self-report, reports, observations). Offspring outcomes needed to be reported as continuous outcomes in order to be able to calculate Hedges' *g* effect sizes. Where applicable, these outcomes were converted to the international system of units (SI), or to equal units (e.g., months to weeks, days to weeks, kilograms to grams). Data was extracted by one author (SG) using a standardized form and fully checked by a second author (MEB). Offspring measures that were reported in less than three studies were excluded from analyses.

Data analysis {#Sec5}
-------------

The effect sizes for all child outcomes were calculated using Hedges' *g* and 95% confidence intervals (CI) to correct for small sample bias. Each effect size thus indicates a standardized comparison between the intervention group and control group. To calculate the pooled effect sizes, we extracted the reported mean scores, standard deviations, and number of participants for each group (intervention and control groups separately) for each offspring measurement. The software program Comprehensive Meta-Analysis^©^ (version 3.0) was used to calculate pooled effect sizes, mean differences, forest plots, heterogeneity, and funnel plots. The effect sizes were interpreted according to Cohen's rule of thumb (small = 0.20--0.49; medium = 0.50--0.79; large = 0.80 and higher). As an indicator of heterogeneity among the effect sizes, we used the *I*^2^ statistics (0% = no heterogeneity to 75% = high heterogeneity). We calculated 95% confidence intervals \[[@CR40]\] around *I*^2^, using the non-central *χ*^2^-based approach within the heterogi module for Stata \[[@CR41]\]. Funnel plots were used to visually inspect for publication bias, which was statistically checked with Egger's test of the intercept and Duval and Tweedie's trim and fill procedure \[[@CR42]\].

A priori, we expected substantial heterogeneity between studies and therefore used a random effects model \[[@CR43]\] in which a pooled effect size was calculated for each offspring outcome, and one random effects model for the overall pooled effect size. Secondly, several post hoc subgroup analyses were performed, in which pooled effect sizes were calculated for the main DSM disorders or symptoms, DSM disorders or symptoms and the offspring outcomes, type of intervention (psychotherapy, supplements or medication, and other), diagnostic status (through clinical interview or self-reported symptoms), risk of bias (high, low), and whether the author indicated a significant and positive effect of the intervention on maternal main DSM disorders or symptoms (yes, no). A mixed effects model was used in the subgroup analyses, where the pooled effect sizes within subgroups were calculated with the random effects model, and the fixed effects model was used to test the difference between subgroups.

Results {#Sec6}
=======

The search yielded 10,160 results up to April 2016. Citations and references of included articles and 207 reviews resulted in 129 additional articles. The search was updated up to August 2017, which resulted in 968 additional articles. A total of 9770 articles were screened after removal of duplicates. The systematic search resulted in 18 eligible articles (0.18%; see Fig. [1](#Fig1){ref-type="fig"} for full details) reporting results of 16 RCTs, which are reported in Table [1](#Tab1){ref-type="table"}. In total, 2778 pregnant women were randomized over 11 different treatment types. Treatment types included (variations of) CBT, massage therapy, psycho-education, relaxation treatments, and couples therapy. Intensity of the interventions ranged from two psycho-education phone sessions up to 16 CBT-based home visits. Details of treatment type, intensity, and the effects on maternal psychopathology are reported in Table [1](#Tab1){ref-type="table"}. Seven studies focused on depression only \[[@CR44]--[@CR50]\], two on both depression and anxiety \[[@CR51], [@CR52]\], three on anxiety only \[[@CR53]--[@CR55]\], two on fear of childbirth \[[@CR56], [@CR57]\], one on posttraumatic stress disorder (PTSD) \[[@CR58]\], one on stress in general \[[@CR59]\], and one on various common mental disorders \[[@CR60]\]. The risk of bias in the included studies was in general high, as reported in Table [1](#Tab1){ref-type="table"}.Fig. 1Flowchart of included studiesTable 1Overview of included studiesAuthor, yearStudy focusSelection criteriaConditions and timing of interventionNo. of participantsAuthors conclude sign. Effect of intervention on mother?Offspring measuresCountryRisk of biasSCBAIROTBastani, 2006 \[[@CR53]\]AnxietySTAI \> 30IG: Applied relaxation training, 7 wk. group sessions\
CG: TAU\
PrenatalIG, 52; CG, 52; Total, 104Yes, on anxiety symptoms*Medical records:*\
BW & GAIran????+--?HCappon, 2015 \[[@CR54]\] ^x^AnxietyBAI ≥ 21IG: Listening to music, 20 to 296 times individually\
CG: TAU\
PrenatalIG, 36; CG, 37; Total, 73Yes, on anxiety symptoms*Questionnaire:*\
BW & GA. *IBQ-r* at age 2 to 3 monthsUSA??++--++LChambers, 2009 \[[@CR55]\] ^x^AnxietySTAI; State or trait subscale\
≥ 40IG: 6 wk. individual relaxation training\
CG: List of tips for reducing stress\
PrenatalIG, 10; CG, 12;\
Total, 22No*Medical records:* BW & GA & Apgar scoresUSA+?--+--+--HFenwick, 2015 \[[@CR56]\]Fear of childbirthW-DEQ\
≥ 66IG: Telephone psycho-education, 2 sessions\
CG: TAU\
PrenatalIG, 91; CG, 93;\
Total, 184Yes, on flashbacks*Medical records:* GA. Hospitalization up to 6 weeksAustralia+----++++LField, 2009 \[[@CR45]\]DepressionSCID diagnosis MDDIG: Massage therapy, 12 wk. sessions\
CG: TAU\
PrenatalIG, 88; CG, 61;\
Total, 149Yes, on depressive symptoms*Medical records:* BW & GA. *Saliva* (cortisol) *& BNBAS* at age 2 daysUSA+?--+------HKaramoozian, 2015 \[[@CR51]\]Depression & AnxietyEPDS \> 9 & PRAQ high scoreIG: 12 wk. group CBSM\
CG: TAU\
PrenatalIG, 14; CG, 15;\
Total, 29Yes, on anxiety and depressive symptoms*Apgar scale:* Apgar scoresIran????++--HMadigan, 2015 \[[@CR58]\]PTSD in adolescentsCPTSDI PTSD diagnosis *or* AAI unresolved state of mindIG: 12 wk. trauma focused CBT plus 12 sessions parenting course\
CG: Parenting course (TAU)\
PrenatalIG, 12; CG, 14; Total, 26No*ASSP* at age 12 monthsCanada???+++--LMaselko, 2015 \[[@CR46]\] ^a\*^DepressionSCID diagnosis MDDIG: Thinking healthy programme (CBT based), 7 wk. visits and 9 monthly visits\
CG: Enhanced routine care\
Prenatal and postpartumIG, 289; CG, 295; Total, 584Yes, less MDD diagnoses in IG*SDQ, SCAS,* weight, height, and BMI at age 7 yearsPakistan+++++----LMilgrom, 2015 \[[@CR50]\]DepressionSCID diagnosis MDD *and* EPDS ≥ 13IG: Beating blues before birth (CBT based), 8 sessions\
CG: TAU\
PrenatalIG, 16; CG, 13;\
Total, 29Yes, on depressive and anxiety symptoms*Medical records:* BW & GA. *IBQ-R, ASQ-3, and ASQ-SE* at age 9 monthsAustralia++?++----MNetsi, 2015 \[[@CR47]\]DepressionCIS diagnosis MDDIG: 12 sessions individual CBT\
CG: TAU\
PrenatalIG, 14; CG, 11;\
Total, 25Yes, on depressive symptoms*Medical records:* BW. *ICQ and BISQ* at age 2 monthsUK++--+--+--HRahman, 2008 \[[@CR44]\]\*DepressionSCID diagnosis MDDIG: Thinking healthy programme (CBT based), 7 wk. visits and 9 monthly visits\
CG: Enhanced routine care\
Prenatal and postpartumIG, 440; CG, 463; Total, 903Yes, on MDD diagnoses*Records*: Weight, height, health at ages 6 and 12 monthsPakistan+++++++LRothberg, 1991 \[[@CR59]\]StressSRRS ≥ 39IG: Psychosocial support during each antenatal clinic visit\
CG: TAU\
PrenatalIG, 43; CG, 43; Total, 86No*Medical records & Ballard score:* BW & GA. *Height, hospitalization* at birthSouth Africa+??+--+--HRouhe, 2013 \[[@CR57]\]Fear of childbirthW-DEQ ≥ 100IG: 6 sessions psycho-educative group therapy\
CG: TAU\
Prenatal and postpartumIG, 131; CG, 240; Total: 371Yes, on fear symptoms*Medical records:* BW & GA & Apgar scores. Arterial Ph. at birthFinland++------+--HUrizar, 2011 \[[@CR48]\]DepressionCES-D ≥ 16 *or* past history of MDDIG: 12 wk. group CBSM\
CG: TAU\
PrenatalIG, 24; CG, 29; Total, 53No*Saliva* (cortisol) at ages 6 and 18 monthsUSA????++--HVerbeek, 2016\[[@CR52]\]^x^Depression & AnxietyEPDS ≥ 12 *or* STAI ≥ 42IG: 10 to 12 sessions individual CBT\
CG: TAU\
Prenatal and postpartumIG, 121; CG, 120; Total, 241No*Medical records:* BW & GA & Apgar scoresNL++--++++LVerbeek, 2016b \[[@CR52]\] ^b\ x^Depression & AnxietyEPDS ≥ 12 *or* STAI ≥ 42IG: 10 to 12 sessions individual CBT\
CG: TAU\
Prenatal and postpartumIG, 97; CG, 99; Total, 196No*CBCL and BSID* at age 18 monthsNL++--++++LVilhena, 2017 \[[@CR60]\]Common mental disorder in obese womenSRQ-20\
≥ 8IG: Homeopathy, 2 times a day, 4 days a week\
CG: Placebo\
PrenatalIG, 62; CG, 72; Total, 134No*Records:*\
GA, BW, Apgar of 10 at 5 min after birthBrazil+++??+--LZhao, 2017 \[[@CR49]\]DepressionEPDS ≥ 9 or PDSS ≥ 20IG: 6 sessions couple-separated psycho-educational program for first time parents\
CG: TAU\
PrenatalIG, 175; CG, 174; Total, 349Yes, on depressive status*Medical records:*\
GA, BWChina+???++?LAll presented studies were randomized controlled trials (RCT), except for \*cluster RCT. ^x^Doctoral dissertation. ^a^Follow-up for Rahman 2008. ^b^Follow-up for Verbeek 2016. *IG* intervention group, *CG* control group, *TAU* treatment as usual, *wk* weekly, *MDD* major depressive disorder, *CBSM* cognitive-behavioral stress management, *CBT* cognitive behavioral therapy, *BW* birth weight, *GA* gestational age, *USA* United States of America, *UK* United Kingdom, *NL* the Netherlands, *BAI* Beck anxiety inventory, *STAI* state trait anxiety inventory, *W-DEQ* Wijma delivery expectancy/experience questionnaire, *SCID* structured clinical interview for DSM disorders, *EPDS* Edinburgh postnatal depression scale, *PRAQ* pregnancy-related anxiety questionnaire, *CPTSDI* children's PTSD inventory, *PTSD* posttraumatic stress disorder, *AAI* adult attachment interview, *MDD* major depressive disorder, *CIS* clinical interview schedule, *SRRS* social readjustment rating scale, *CES-D* Centre for Epidemiological Studies depression Scale, *SRQ-20* self-report questionnaire, *IBQ-R* infant behaviour questionnaire revised, *ASQ-3* ages and stages questionnaire, *ASQ-SE* ages and stages questionnaire social emotional, *SDQ* strengths and difficulties questionnaire, *SCAS* Spence children's anxiety scale, *ASSP* Ainsworth strange situation procedure, *BNBAS* Brazelton neonatal behaviour assessment scale, *ICQ* infant characteristic questionnaire, *BISQ* brief infant sleep questionnaire, *BSID* Bayley scales of infant development, *CBCL* child behaviour checklist. Risk of bias criteria are represented as *S* = sequence generation, C = allocation concealment, B = blinding of participants and personnel, A = blinding of outcome assessors, I = incomplete outcome data, R = selective reporting, O = other sources of bias, and are coded as + = low risk of bias (0 points), − = high risk of bias (2 points),? = unclear risk of bias (1 point). T = total risk of bias, in which H = high risk of bias, L = low risk of bias. Total risk of bias is scored as \< 6 = low risk, \> 6 high risk

The included studies reported 28 different offspring outcome measures. Most outcomes were reported in a single study only. Analyses were restricted to the outcomes that were reported in at least three studies, which resulted in three eligible outcomes: birth weight, Apgar (1, 5, and 10 min combined), and gestational age (Fig. [2](#Fig2){ref-type="fig"}). For five studies, it was therefore not possible to aggregate any of the reported offspring outcomes in the meta-analysis, both in terms of target outcome (e.g., cognitive vs. emotional development) and measurement instrument. Effect sizes of the removed outcomes for each study are reported in Fig. [3](#Fig3){ref-type="fig"}. The mean values for each included study, and the overall highest and lowest values on the three offspring outcomes are displayed in Table [2](#Tab2){ref-type="table"}.Fig. 2Forest plots for Apgar scores, birth weight, and gestational age. BW = birth weight, GA = gestational age, *g* = Hedges' *g*, mixed = combination of multiple common mental disorders and/or symptomsFig. 3Forest plots of excluded offspring outcomes*. g* = Hedges' *g*, mixed = combination of multiple common mental disorders and/or symptoms, combined = combination of multiple offspring outcomes and/or timing of offspring outcomes, PPD = peripartum depression, ASSP Disorg = Ainsworth stranger situation disorganized attachment measure, BSID Cognitive = Bayley scales of infant development-cognitive subscale, difficult temp = difficult temperament

Since there were no RCTs of pharmacological interventions during pregnancy reporting offspring outcomes, data from 11 non-pharmacological RCTs (reported in 13 articles) were analyzed. First, pooled effect sizes for each selected outcome were calculated. Outcomes of the meta-analysis are reported in Table [3](#Tab3){ref-type="table"} and displayed in Fig. [2](#Fig2){ref-type="fig"}. Birth weight was not significantly affected by interventions as compared to control conditions, corresponding to a mean difference of 42.88 g (95% CI − 33.06 to 118.83, *N* = 11, *n* = 1583, *I*^2^ = 39% \[[@CR45], [@CR47], [@CR49], [@CR50], [@CR52]--[@CR55], [@CR57], [@CR59], [@CR60]\]) between the intervention and control groups. Gestational age and Apgar scores did not significantly improve or worsen by prenatal interventions (gestational age mean difference = 0.08 weeks \[95% CI −0.09 to 0.24\], *N* = 10, *n* = 1669, *I*^2^ = 0% \[[@CR49], [@CR50], [@CR52], [@CR53], [@CR55]--[@CR57], [@CR59], [@CR60]\]; Apgar mean difference = 0.21 \[95% CI −0.28 to 0.71\], *N* = 4, *n* = 663, *I*^2^ = 68% \[[@CR51], [@CR52], [@CR55], [@CR57]\]). The pooled effect size indicated an overall non-significant effect on Apgar scores, birth weight, and gestational age together. Since these three offspring outcomes are heterogeneous in interpretation, this overall result is not further discussed. Heterogeneity across the outcomes was low, *I*^2^ = 23% (95% CI 0--60%). There was some indication of publication bias, as indicated by Duval and Tweedie's trim and fill procedure (studies trimmed = 2, adjusted *g* = 0.05, 95% CI −0.05 to 0.15). Visual inspection of the funnel plot and the Egger's test (*p* = 0.16) did not indicate publication bias. The evidence for each of the three pooled effect sizes was downgraded using the GRADE assessment to very low certainty of evidence. For each of the outcomes, there was a serious risk of bias, consistency in measures, serious indirectness, and serious imprecision. Birth weight and gestational age were rated as important outcomes, and Apgar scores were rated as not important.Table 2Study offspring outcomesAuthor, yearMean birth weight (Sd.) in gramsMean Apgar score (Sd.)Mean gestational age (Sd.) in weeksBastani, 2006 \[[@CR53]\]IG, 3168 (420)\
CG, 2883 (640)n/aIG, 38 (5.9)\
CG, 38 (4.4)Cappon, 2015 \[[@CR54]\]IG, 3366 (523)\
CG, 3344 (773)n/an/aChambers, 2009 \[[@CR55]\]IG, 3232 (695)\
CG, 3562 (529)IG, Apgar 1 min: 7.8 (1.3)\
CG, Apgar 1 min: 8 (1.1)\
IG, Apgar 5 min: 8.5 (0.7)\
CG, Apgar 5 min: 9.1 (0.3)IG, 38.4 (2.5)\
CG, 39.5 (1.4)Fenwick, 2015 \[[@CR56]\]n/an/aIG, 39.2 (1.6)\
CG, 39.1 (2.0)Field, 2009 \[[@CR45]\]IG, 3318 (360)\
CG, 3226 (492)n/aIG, 39 (1.2)\
CG, 38.7 (1.6)Karamoozian, 2015 \[[@CR51]\]n/aIG, Apgar 1 min: 8.9 (0.3)\
CG, Apgar 1 min: 8.1 (0.8)\
IG, Apgar 5 min: 9.7 (0.5)\
CG, Apgar 5 min: 9.3 (0.7)n/aMilgrom, 2015 \[[@CR50]\]IG, 3626 (786)\
CG, 3575 (595)n/aIG, 40 (1)\
CG, 40 (2)Netsi, 2015 \[[@CR47]\]IG, 3423 (503)\
CG, 3180 (871)n/an/aRothberg, 1991 \[[@CR59]\]IG, 3214 (649)\
CG, 3113 (690)n/aIG, 38.7 (3)\
CG, 38.3 (2.7)Rouhe, 2013 \[[@CR57]\]IG, 3532 (550)\
CG, 3486 (518)IG, Apgar 1 min: 8.7 (1.1)\
CG, Apgar 1 min: 8.5 (1.4)\
IG, Apgar 5 min: 9.3 (1.0)\
CG, Apgar 5 min: 9.1 (1.2)\
IG, Apgar 10 min: 9.7 (0.8)\
CG, Apgar 10 min: 9.5 (0.9)IG, 39.7 (1.5)\
CG, 39.6 (1.6)Verbeek, 2016; Verbeek, 2016b \[[@CR52]\]IG, 3419 (651)\
CG, 3474 (561)IG, Apgar 1 min: 8.6 (n/a)\
CG, Apgar 1 min: 8.6 (n/a)\
IG, Apgar 5 min: 9.5 (n/a)\
CG, Apgar 5 min: 9.5 (n/a)\
IG, Apgar 10 min: 9.8 (n/a)\
CG, Apgar 10 min: 9.8 (n/a)IG, 38.9 (2.3)\
CG, 39.2 (1.8)Vilhena, 2017 \[[@CR60]\]IG, 3390 (440)\
CG, 3270 (560)n/aIG, 39.4 (1.2)\
CG, 38.9 (1.9)Zhao, 2017 \[[@CR49]\]IG, 3256 (522)\
CG, 3349 (529)n/an/aCombined range per offspring outcomeLowest value, 2883\
Highest value, 3626Lowest value, 7.8\
Highest value, 9.8Lowest value, 38\
Highest value, 40*IG* intervention group, *CG* control groupTable 3Meta-analyses and subgroup analyses results*N*No. of participants*g*95% CI*pI* ^2^95% CI*p* ^a^Effect of prenatal interventions on offspring outcomes (BW, GA, Apgar)All studies \[[@CR45], [@CR47], [@CR49]--[@CR57], [@CR59], [@CR60]\]1317960.09− 0.03 to 0.210.14230--60Effect of prenatal interventions for each offspring outcomeBW \[[@CR45], [@CR47], [@CR49], [@CR50], [@CR52]--[@CR55], [@CR57], [@CR59]\]1115830.08− 0.06 to 0.220.27390--70GA \[[@CR49], [@CR50], [@CR52], [@CR53], [@CR55]--[@CR57], [@CR59], [@CR60]\]1016690.03− 0.06 to 0.130.4900--53Apgar \[[@CR51], [@CR52], [@CR55], [@CR57]\]46630.13− 0.28 to 0.540.53680--87Subgroup analyses Type of diagnosis\*Anxiety \[[@CR52]--[@CR57]\]6852− 0.01− 0.22 to 0.200.89400--750.41 BW \[[@CR52]--[@CR55], [@CR57]\]56680− 0.33 to 0.3217022--88 GA \[[@CR52]--[@CR56]\]5779− 0.06− 0.24 to 0.120.54270--71Depression \[[@CR45], [@CR47]--[@CR50]\]55750.02− 0.15 to 0.180.8600--79 BW \[[@CR45], [@CR47]--[@CR50]\]55750.01− 0.20 to 0.230.90220--68 GA \[[@CR45], [@CR48]--[@CR50]\]45500.05− 0.12 to 0.210.5800--85Other \[[@CR51], [@CR52], [@CR59], [@CR60]\]42830.22− 0.90 to 0.540.17620--85 BW \[[@CR52], [@CR59], [@CR60]\]32540.06− 0.15 to 0.270.57220--97 GA \[[@CR52], [@CR59], [@CR60]\]32540.07− 0.19 to 0.330.60450--84 Risk of biasHigh \[[@CR45], [@CR47], [@CR51], [@CR53], [@CR55], [@CR57], [@CR59]\]77860.21− 0.00 to 0.42*0.05*310--700.09Low \[[@CR49], [@CR50], [@CR52], [@CR54], [@CR56], [@CR60]\]61010− 0.00− 0.13 to 0.120.9700--61 Diagnosis through clinical interview or self-reportClinical interview \[[@CR45], [@CR47], [@CR50]\]32030.20− 0.07 to 0.470.1500--900.43Self-report \[[@CR49], [@CR51]--[@CR60]\]1015930.08− 0.06 to 0.220.28360--70 Type of interventionPsychotherapy \[[@CR47], [@CR49]--[@CR52], [@CR57], [@CR59]\]711300.08− 0.10 to 0.270.40390--750.67Other \[[@CR45], [@CR53]--[@CR56], [@CR60]\]66660.13− 0.02 to 0.280.0900--74 Report of sign. Effect of intervention on mother?No \[[@CR52], [@CR55], [@CR59], [@CR60]\]44830.05− 0.18 to 0.280.68310--750.64Yes \[[@CR45], [@CR47], [@CR49]--[@CR51], [@CR53], [@CR54], [@CR56], [@CR57]\]913130.11− 0.04 to 0.260.14290--67^a^The *p* value indicates whether the subgroups differ from each other. *g* = Hedges' *g*, 95% CI = confidence interval 95% of Hedges' *g*. \*In this subgroup analysis, the Verbeek 2016 study subgroups depression, anxiety, and combined (other) were analyzed separately. *BW* birth weight, *GA* gestational age. Superscript numbers refer to included studies in each analysis

Table [3](#Tab3){ref-type="table"} displays several subgroup analyses. Studies targeting depression and anxiety, or with a focus on other disorders, did not show a significant pooled effect size, hence did not improve offspring outcomes based on the three selected outcomes. According to the mixed effects analysis, the subgroups did not differ significantly. When investigating the separate offspring outcomes for each disorder (depression, anxiety, and other), it appeared that there was no significant effect of intervention on offspring outcomes within each disorder. The overall effect size in the risk of bias subgroup analysis was not significant. Although studies with a high risk of bias were significantly related to positive birth outcomes (*g* = 0.21, 95% CI 0.00 to 0.42, *p* = 0.05, *N* = 7, *n* = 786, *I*^2^ = 31% \[[@CR45], [@CR47], [@CR51], [@CR53], [@CR55], [@CR57], [@CR59]\]), the mixed effects analysis indicated no significant difference between high and low risk of bias studies (*p* = 0.09). The method through which the (possible) diagnosis was established, i.e., through clinical interview or self-report, whether the authors reported that the intervention had a significant effect on treating maternal common mental disorder (symptoms) compared to the control group, and the type of intervention (psychotherapy versus other types), did not significantly affect offspring outcomes, nor did the mixed effects analyses show differences between the subgroups (Table [3](#Tab3){ref-type="table"}).

Discussion {#Sec7}
==========

Leading international clinical guidelines \[[@CR1], [@CR2]\] recommend screening and treatment of pregnant women for mental disorders and symptoms, with the clinical view to additionally prevent adverse effects on the offspring. The systematic search identified 16 non-pharmacological RCTs, including 14 psychological interventions that reported offspring outcomes. The results from the current meta-analysis indicate that non-pharmacological interventions do not have a significant effect on improving birth outcomes, and their effects could not be meta-analyzed for (developmental) offspring outcomes. Therefore, based on the current evidence, there is no strong indication of prophylactic effects. Although no statistically significant result was obtained for birth weight, all effect sizes within the 95% confidence interval around the pooled effect estimate were small, indicating that the true effect of prenatal interventions on birth weight is most likely small. Furthermore, the quality of most studies was low and the studies were relatively heterogeneous. An explanation for the non-significant effect size may be a ceiling effect since offspring in the control and intervention groups had a birth weight within the normal range. The birth weight in the trials ranged from 2883 to 3626 g, indicating there was no low birth weight according to the worldwide standards for low birth weight, that is less than 2500 g \[[@CR61]\].

Secondly, the meta-analysis did not show that the somatic outcomes indexed by Apgar scores and gestational age were significantly associated with the non-pharmacological interventions. As for birth weight, the confidence intervals around the pooled effect estimates for Apgar scores and gestational age indicate that a true effect is most likely small. It was furthermore not possible to investigate the impact of prenatal interventions on preventing preterm birth, since the included studies had different definitions of preterm birth (different gestational age), or did not report enough information to calculate effect sizes. Additionally, five out of 16 studies reported different measures of (long term) offspring outcomes. It was therefore not possible to investigate the effects of interventions on non-somatic outcomes, such as psychopathology or developmental problems. Although previous research and clinical guidelines \[[@CR1], [@CR2]\] report on harmful effects of prenatal mental disorders on offspring, including an increased risk of low birth weight \[[@CR6]\], the current meta-analysis could not support the notion that treatment can mitigate this effect. Furthermore, the current results did not indicate that pregnant women in the care as usual or placebo groups had worse or better offspring outcomes. This is to some extent in contrast to a recent meta-analysis, in which it was concluded that prenatal preventive and acute interventions for MDD (symptoms) improved overall child functioning. This effect was however primarily based upon preventive interventions and offspring behaviour \[[@CR26]\].

The current meta-analysis found zero RCTs on the effects of antenatal treatment of common mental disorders with medication (i.e., antidepressants) on offspring. This is noteworthy given the fact that antidepressant medication is one of the most used treatments during pregnancy \[[@CR22]\]. Furthermore, previous reviews of non-randomized trials indicate an association between prenatal antidepressant use and adverse offspring outcomes, including lower birth weight, preterm birth, lower Apgar scores \[[@CR27], [@CR62]\], and cardiovascular malformations \[[@CR32]\]. Correspondingly, untreated maternal mental disorders has been associated with similar adverse effects, which in turn are linked to other subsequent offspring problems \[[@CR7]\]. Other studies suggest that the effects of antidepressants on offspring might be minimal \[[@CR63]--[@CR65]\]. Due to the nature of the studies (non-randomized cohort trials), there is insufficient evidence of the possible effects of prenatal antidepressant usage. It is therefore not clear what the net effects of antidepressants are for offspring. RCTs and comparative treatment trials are needed to disentangle whether these offspring outcomes are related to antidepressant use or are predominantly the result of the mental disorders of the mother. To estimate the (enduring) relative effects of pharmacological and non-pharmacological interventions on offspring, a RCT comparing the two intervention types may provide more information on the prophylactic effects on offspring. Such design would be more ethical since the pregnant woman receives treatment according to clinical recommendations. Moreover, it would provide more information on the effects of antidepressants.

Collectively, the findings of the meta-analysis indicate that there is insufficient data to support the beneficial effects of prenatal treatments on offspring and that more research on the effects of prenatal treatments on offspring is needed. These results of the meta-analysis must be interpreted in the context of some limitations. In general, the included trials had a high risk of bias and reported different offspring outcomes, and the GRADE assessment indicated very low certainty of evidence, thereby limiting the results. Overall, there is some indication that non-pharmacological interventions may have a positive influence on offspring birth weight; however, the effect was not significant and could be overestimated due to the small samples sizes and high risk of bias. The small sample size of pregnant women, and the small amount of included studies, increases the risk of false-positive and false-negative birth outcomes. Furthermore, other birth outcomes including preterm birth, low birthweight for gestational age, or child development could not be analyzed due to the inconsistent reporting and lack of studies. There is no conclusive evidence that interventions aimed to target prenatal mental disorders are beneficial or iatrogenic for offspring, especially with regard to long-term and psychological impact.

For health care professionals, there is little evidence that prenatal non-pharmacological interventions are beneficial for the offspring with respect to birth weight, gestational age, and Apgar scores. There is not enough support that commonly used treatments for prenatal mental disorders are beneficial to offspring and hence do not provide a scientific foundation to support recommendations of specific treatment options with respect to the benefit for the child. More systematic research with long-term follow-up of the offspring is consequently needed to support (inter)national guidelines for prenatal mental disorders. As a first step, research on prenatal interventions may register birth outcomes from birth reports of (former) participants in RCTs. RCTs focusing on pharmacological interventions as compared to psychotherapy during pregnancy are needed, even though this may be challenging due to ethical considerations and preferences of pregnant women and their health care providers.

Conclusions {#Sec8}
===========

The results from the current meta-analysis indicate no significant effects of non-pharmacological interventions on improving birth outcomes. No firm conclusion of prophylactic effects can be drawn due to the reported limitations. Despite the recommendation of leading international clinical guidelines \[[@CR1], [@CR2]\] to routinely screen pregnant women for common mental disorders and symptoms, and subsequently treat the mother to reduce perinatal symptomatology and prevent adverse effects on the offspring, there is insufficient data to support the clinical recommendation regarding the safety of prenatal treatments for the offspring. Prior research implies that prenatal interventions improve maternal psychopathology \[[@CR24], [@CR26]\], yet more research is warranted to draw stronger conclusions on the impact of prenatal interventions on offspring, especially regarding child development. Potential adverse effects on offspring cannot be ruled out, thereby underscoring the urgent need for properly controlled trials to best inform care approaches for mothers and their offspring.
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AD

:   Antidepressant medication

CBT

:   Cognitive behavioral therapy

CI

:   Confidence intervals

PPHN

:   Persistent pulmonary hypertension

PTSD

:   Posttraumatic stress disorder

RCT

:   Randomized controlled trial

Not applicable.

Funding {#FPar1}
=======

Not applicable.

Availability of data and materials {#FPar2}
==================================

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

MEB, SG, and CLB designed the study and study proposal. MEB and SG assessed studies for eligibility, designed data collection tools, and extracted and systematically scored all information from included articles. CLB was the third rated to reach consensus. MEB, SG, and PC analyzed the data, and all authors interpreted the results. MEB, AW, SG, and CLB drafted the article. All authors critically revised the article and approved the final version.

Ethics approval and consent to participate {#FPar3}
==========================================

Not applicable.

Consent for publication {#FPar4}
=======================

Not applicable.

Competing interests {#FPar5}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
